TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15494100

Group type: EXPERIMENTAL
Intervention: 1 mg E(2)V + 2.5 mg MPA
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 2 mg E(2)V + 5 mg MPA
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 2 mg E(2)V + 2.5 mg MPA
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 1 mg E(2)V + 5 mg MPA
Number of subjects: 419
Study: 11806199

Group type: EXPERIMENTAL
Intervention: Laser therapy (intravenous and supravenous)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (no laser radiation)
Number of subjects: 173
Study: 10193280

Group type: EXPERIMENTAL
Intervention: i.v. ketamine 10 mg i.v. bolus followed by 10 mg h‐1 infusion for 48 h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8164327

Group type: EXPERIMENTAL
Intervention: PGE1 infusion at a rate of 30 ng.kg‐1 x min‐1 during surgery and 10‐30 ng.kg‐1 x min‐1 after surgery
Number of subjects: 12

Group type: COMPARATOR
Intervention: No PGE1 infusion (control group)
Number of subjects: 12
Study: 3284285

Group type: EXPERIMENTAL
Intervention: Oxygen therapy with mechanical ventilation (Group B)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oxygen therapy only (Group A)
Number of subjects: 69
Study: 29690729

Group type: EXPERIMENTAL
Intervention: NEO‐GAIT
Number of subjects: 60

Group type: COMPARATOR
Intervention: CPM
Number of subjects: 60
Study: 27130908

Group type: EXPERIMENTAL
Intervention: CT-P13 (3 mg/kg) administered intravenously every 8 weeks from weeks 62 to 102, with concomitant methotrexate.
Number of subjects: 302

Group type: COMPARATOR
Intervention: RP (Remicade) for 54 weeks followed by CT-P13 (3 mg/kg) administered intravenously every 8 weeks from weeks 62 to 102, with concomitant methotrexate.
Number of subjects: 302
Study: 26206177

Group type: EXPERIMENTAL
Intervention: ProSeal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Classic
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Supreme
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: air-Q
Number of subjects: 32

Group type: COMPARATOR
Intervention: All SGDs
Number of subjects: 32

Group type: COMPARATOR
Intervention: ProSeal and Classic
Number of subjects: 32
Study: 24282495

Group type: EXPERIMENTAL
Intervention: Joint Crisis Plans (JCP) plus treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint Crisis Plans (JCP)
Number of subjects: 0
Study: 21955538

Group type: EXPERIMENTAL
Intervention: Stroke volume guided intra‐operative fluid management using LiDCOplus with maintenance fluid and 250 ml colloid boluses to achieve sustained 10% increases in stroke volume
Number of subjects: 128

Group type: COMPARATOR
Intervention: Fluid administration at the responsible (blinded) anaesthetist's discretion
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Stroke volume guided intra‐operative fluid management
Number of subjects: 128
Study: 18981885

Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty (Prestige ST and Bryan)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 93
Study: 16534549

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) continued for 6 weeks in group A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atorvastatin withdrawn in group B
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atorvastatin started in groups C and D for 6 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atorvastatin withdrawn in group C after 6 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atorvastatin continued in group D after 6 weeks
Number of subjects: 40
Study: 12669756

Group type: EXPERIMENTAL
Intervention: Acoustically salient prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less salient prime
Number of subjects: 0
Study: 14559927

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily for 21 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10468218

Group type: EXPERIMENTAL
Intervention: L-DOPA treatment in PD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal subjects and untreated PD patients)
Number of subjects: 0
Study: 7644905

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 100
Study: 2670950

Group type: EXPERIMENTAL
Intervention: AO dynamic hip-screw
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 984277

Group type: EXPERIMENTAL
Intervention: Scrub Method
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Scrub-Floss Method
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Bass Method
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Bass-Floss Method
Number of subjects: 311

Group type: COMPARATOR
Intervention: Comparison group (no supervised instructions)
Number of subjects: 311
Study: 28885111

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bilateral tDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 25853905

Group type: EXPERIMENTAL
Intervention: 2-mg intraventricular TPA every 12 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo every 12 hours
Number of subjects: 12
Study: 24012128

Group type: COMPARATOR
Intervention: Oral antibiotic treatment (group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Local antibiotic treatment (group 2)
Number of subjects: 90
Study: 21835135

Group type: EXPERIMENTAL
Intervention: Mepolizumab (0.55, 2.5, or 10 mg/kg) administered every 4 weeks for a total of 3 infusions
Number of subjects: 59
Study: 19558371

Group type: EXPERIMENTAL
Intervention: Diabetes Symptoms Checklist‐Revised (DSC‐R)
Number of subjects: 4000
Study: 17942818

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV (subgroup with migraine lasting longer than 72 hours)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo (subgroup with migraine lasting longer than 72 hours)
Number of subjects: 205
Study: 15083429

Group type: EXPERIMENTAL
Intervention: Intensive Functional Rehabilitation (IFR)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 77
Study: 11490806

Group type: EXPERIMENTAL
Intervention: Regional targeting chemoimmunotherapy (Group A, n = 44 patients)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Systemic chemoimmunotherapy (Group B, n = 42 patients)
Number of subjects: 86
Study: 9506650

Group type: EXPERIMENTAL
Intervention: Milrinone lactate (50 microg/kg loading dose, then 0.5 microg/kg/min infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Milrinone lactate (after discontinuation of infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Milrinone lactate (during infusion)
Number of subjects: 20
Study: 7635035

Group type: EXPERIMENTAL
Intervention: Synthetic human growth hormone (GH)
Number of subjects: 0
Study: 3051628

Group type: EXPERIMENTAL
Intervention: Orchiectomy plus combined hormone and chemotherapy (ethinylestradiol sulfonate plus vincristine/vinblastine, cyclophosphamide, methotrexate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchiectomy plus antigonadotropic therapy alone (ethinylestradiol sulfonate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchiectomy plus chemotherapy (vincristine/vinblastine, cyclophosphamide, methotrexate)
Number of subjects: 0
Study: 31006879

Group type: EXPERIMENTAL
Intervention: Early nutrition within 48 hours after ICU admission (E+ group)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Delayed nutrition or no nutrition (E- group)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Early nutrition (E+ group)
Number of subjects: 203
Study: 31136113

Group type: EXPERIMENTAL
Intervention: mirabegron 50mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: solifenacin 5mg
Number of subjects: 62
Study: 28973318

Group type: EXPERIMENTAL
Intervention: IOL repositioning by scleral suturing 1.5- to 2-mm posterior to limbus
Number of subjects: 104

Group type: COMPARATOR
Intervention: IOL exchange with a retropupillar iris-claw IOL using a 5.5-mm scleral pocket incision
Number of subjects: 104
Study: 26377161

Group type: EXPERIMENTAL
Intervention: Lowest quintile of serum retinol (s-retinol)
Number of subjects: 21774

Group type: COMPARATOR
Intervention: Middle quintile of serum retinol (s-retinol)
Number of subjects: 21774

Group type: EXPERIMENTAL
Intervention: Upper quintile of serum retinol (s-retinol)
Number of subjects: 21774

Group type: EXPERIMENTAL
Intervention: Low retinol concentrations
Number of subjects: 21774

Group type: EXPERIMENTAL
Intervention: Serum concentrations of 25-hydroxyvitamin D
Number of subjects: 21774
Study: 23388005

Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing (2% chlorhexidine-impregnated washcloths)
Number of subjects: 7727

Group type: COMPARATOR
Intervention: Nonantimicrobial washcloths
Number of subjects: 7727
Study: 21198560

Group type: EXPERIMENTAL
Intervention: Furosemide 80mg IV bolus
Number of subjects: 59

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 59
Study: 20042080

Group type: EXPERIMENTAL
Intervention: D2 measure of diversity in meta-analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: I2 measure of inconsistency in meta-analysis
Number of subjects: 0
Study: 17090809

Group type: EXPERIMENTAL
Intervention: High-intensity physical activity counseling
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 165

Group type: COMPARATOR
Intervention: Attention control counseling
Number of subjects: 165
Study: 15159134

Group type: EXPERIMENTAL
Intervention: Valerian extract (600, 1200, and 1800 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diazepam (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11319170

Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (13‐cRA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 9222733

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily in the morning
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg once daily in the evening
Number of subjects: 12
Study: 8203443

Group type: EXPERIMENTAL
Intervention: Indwelling Foley catheter for 24 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: No catheter
Number of subjects: 100
Study: 3584298

Group type: EXPERIMENTAL
Intervention: Habit Reversal (HR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Differential Reinforcement of Other Behaviour (DRO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 30
Study: 29260291

Group type: EXPERIMENTAL
Intervention: Telephone calls (PC)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No phone calls (no PC)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Alendronate persistence after 1 year
Number of subjects: 119
Study: 28725977

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (60,000 IU orally, weekly for 4 weeks) and calcium supplements (500 to 1,000 mg/day for 3 months)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium supplementation
Number of subjects: 43
Study: 25222850

Group type: EXPERIMENTAL
Intervention: Telephone counselling for parents
Number of subjects: 512

Group type: COMPARATOR
Intervention: Standard self-help brochure (Control)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Prolonged abstinence
Number of subjects: 512
Study: 23279924

Group type: EXPERIMENTAL
Intervention: Past 30‐day daily average number of cigarettes smoked
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Tobacco dependence screener (TDS) in buprenorphine condition
Number of subjects: 131

Group type: COMPARATOR
Intervention: Tobacco dependence screener (TDS) in methadone condition
Number of subjects: 131
Study: 21991566

Group type: EXPERIMENTAL
Intervention: Post-operative treatment with FPANS 100 μg q.i.d.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Not treated post-operatively with topical glucocorticoids
Number of subjects: 35
Study: 17192770

Group type: EXPERIMENTAL
Intervention: 600 mg rifampin (intravenous 30-min infusion)
Number of subjects: 11
Study: 14704836

Group type: EXPERIMENTAL
Intervention: High sodium diet (250 mmol)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low sodium diet (20 mmol)
Number of subjects: 41
Study: 11641511

Group type: EXPERIMENTAL
Intervention: IL1B/IL1RN haplotypes
Number of subjects: 590
Study: 9840896

Group type: EXPERIMENTAL
Intervention: Bucket-handle tears (group B, n = 12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Flap tears (group F, n = 15)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Degenerative tears (group D, n = 8)
Number of subjects: 35

Group type: COMPARATOR
Intervention: All groups (n = 35)
Number of subjects: 35
Study: 8084699

Group type: EXPERIMENTAL
Intervention: Random group (2 additional batting-practice sessions each week for 6 weeks, 12 sessions total)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blocked group (2 additional batting-practice sessions each week for 6 weeks, 12 sessions total)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no additional practice)
Number of subjects: 30
Study: 2737307

Group type: EXPERIMENTAL
Intervention: High-dose single agent cisplatinum (19 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Total abdominal and pelvic irradiation (3 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Negative second-look laparotomy
Number of subjects: 120
Study: 30597021

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 8 hours (q8h)
Number of subjects: 2192

Group type: COMPARATOR
Intervention: Ceftaroline fosamil 600 mg every 12 hours (q12h)
Number of subjects: 2192
Study: 30646391

Group type: EXPERIMENTAL
Intervention: 10 mg THC (smoked)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 10 mg THC (vaporized)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 25 mg THC (smoked)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 25 mg THC (vaporized)
Number of subjects: 17
Study: 27500873

Group type: EXPERIMENTAL
Intervention: Pregabalin (up to 600 mg a day for six days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clonidine (up to 600 micrograms a day)
Number of subjects: 34
Study: 24812898

Group type: EXPERIMENTAL
Intervention: Chinese medical enema for brain resuscitation, relieving rigidity of muscles and activating collaterals for 14 days, alongside comprehensive rehabilitation training and intravenous Monosialotetrahexosylganglioside Sodium Injection for 10 days
Number of subjects: 111

Group type: COMPARATOR
Intervention: Comprehensive rehabilitation training and intravenous Monosialotetrahexosylganglioside Sodium Injection for 10 days
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both treatment and control groups
Number of subjects: 111
Study: 23176129

Group type: EXPERIMENTAL
Intervention: 1,000 mg of calcium carbonate combined with 400 IU of vitamin D(3)
Number of subjects: 4143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4143
Study: 20079704

Group type: EXPERIMENTAL
Intervention: Age at first live birth <25 years and >or=3 pregnancies
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Postmenopausal status
Number of subjects: 1357
Study: 17091486

Group type: EXPERIMENTAL
Intervention: VDC/IE
Number of subjects: 388

Group type: COMPARATOR
Intervention: IRS-IV
Number of subjects: 388
Study: 16364108

Group type: EXPERIMENTAL
Intervention: Original PEDro scale guidelines
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Revised PEDro scale guidelines
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Revised definitions for 'less than 15% dropout' and 'point measures and variability'
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PEDro scale items
Number of subjects: 140
Study: 12544314

Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 5 mg daily for 14 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10817352

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoendocrine therapy followed by surgery
Number of subjects: 283

Group type: COMPARATOR
Intervention: Adjuvant chemoendocrine treatment after primary surgery
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoendocrine therapy
Number of subjects: 283
Study: 8639721

Group type: EXPERIMENTAL
Intervention: Survival curves presentation
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Point estimates presentation
Number of subjects: 236
Study: 1519498

Group type: EXPERIMENTAL
Intervention: MLCu375 IUD
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: TCu220C IUD
Number of subjects: 1536

Group type: COMPARATOR
Intervention: Stainless Steel Ring
Number of subjects: 1536

Group type: COMPARATOR
Intervention: Uterine Cavity‐Shaped Device
Number of subjects: 1536
Study: 6825540

Group type: EXPERIMENTAL
Intervention: Granulated pancreatic enzyme preparation (Pankreon)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 19
Study: 31340899

Group type: EXPERIMENTAL
Intervention: Psychological preparation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (basic preparation)
Number of subjects: 118
Study: 30134990

Group type: EXPERIMENTAL
Intervention: Parenting intervention providing training in dialogic book-sharing, conducted weekly for 7 weeks.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition (no intervention).
Number of subjects: 12
Study: 26808860

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (5,000 IU per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 0
Study: 24445955

Group type: EXPERIMENTAL
Intervention: Extended caffeine treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 95
Study: 22585223

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin and 900 mg rifapentine twice weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin and 1,200 mg rifapentine once weekly
Number of subjects: 0
Study: 19188848

Group type: EXPERIMENTAL
Intervention: Exercise program (12-month moderate-to-vigorous exercise combining aerobic and muscle strength training)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 189
Study: 17355800

Group type: EXPERIMENTAL
Intervention: Remifentanyl infusion at 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl bolus injection at 1.5 microg x kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanyl infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl bolus injection
Number of subjects: 60
Study: 15833578

Group type: EXPERIMENTAL
Intervention: mecamylamine (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: mecamylamine + denicotinized cigarettes
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 11792331

Group type: EXPERIMENTAL
Intervention: Iridium-192 gamma radiation
Number of subjects: 685

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Gamma radiation
Number of subjects: 685
Study: 10421597

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1577
Study: 7675578

Group type: EXPERIMENTAL
Intervention: Violent videotape (high arousal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bird-nest-building videotape (low arousal)
Number of subjects: 0
Study: 1683411

Group type: EXPERIMENTAL
Intervention: tertatolol 5 mg o.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 6123884

Group type: EXPERIMENTAL
Intervention: Ivermectin 30 micrograms/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ivermectin 50 micrograms/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ivermectin 5 micrograms/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ivermectin 10 micrograms/kg
Number of subjects: 32
Study: 31420397

Group type: EXPERIMENTAL
Intervention: Reduced duration prophylaxis up to month +3 followed by immuno-guided prophylaxis using QuantiFERON-CMV technique up to month +12
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual prophylaxis strategy up to month +6 followed by pre-emptive therapy up to month +12
Number of subjects: 150
Study: 30066184

Group type: EXPERIMENTAL
Intervention: Thermoplastic aligners (clear transparent PET-G thermoplastic sheets)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-ligating fixed appliances with nickel-titanium archwires
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 26963896

Group type: EXPERIMENTAL
Intervention: Rapid intravenous rehydration (3 litres Hartman's solution over 6 hours) and ongoing midwifery telephone support
Number of subjects: 53

Group type: COMPARATOR
Intervention: Routine in-patient care (control group)
Number of subjects: 53
Study: 23298702

Group type: EXPERIMENTAL
Intervention: Music therapy (30-minute musical session with headset)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (usual setting of an intensive care unit)
Number of subjects: 44
Study: 21466589

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (0.1%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 17643519

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 22
Study: 17074021

Group type: EXPERIMENTAL
Intervention: rebamipide (100 mg, t.i.d.)
Number of subjects: 81

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study: 14561278

Group type: EXPERIMENTAL
Intervention: Oral creatine supplementation (5 g d(‐1) for six weeks)
Number of subjects: 45
Study: 10636278

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 460
Study: 9292483

Group type: EXPERIMENTAL
Intervention: Expiratory-flow limitation during exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal exercise without expiratory-flow limitation
Number of subjects: 9